All In Biotech

Drug Trial Radar · NCT07705737

Rademikibart IV for Acute Asthma and COPD Exacerbation

A Phase 2, Open-Label, Single-Arm Trial to Evaluate IV Rademikibart as an Add-on Treatment for Acute Exacerbation in Participants With Asthma and or COPD With Type 2 Inflammation

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Aug 21, 2026

Primary completion

Dec 2026

Study completion Jan 2027

Sponsor

Lead sponsor
Connect Biopharm LLCIndustry
Sponsor type
Industry
First posted
Jul 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2, open-label, single-arm trial to evaluate IV rademikibart as an add-on treatment for acute exacerbation in participants with asthma or COPD with type 2 inflammation

Conditions

  • Asthma Acute
  • COPD Exacerbation Acute

Interventions

  • RademikibartDrug

    Single 300 mg dose as a 2-minute IV push

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in post-BD FEV1Time frame: 1 week

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Columbus Clinical Services, LLC

    Miami, Florida · Active not recruiting

  • Pharmax Research of South Florida, Inc.

    Miami, Florida · Recruiting

  • Washington University- Cardiovascular Imaging and Clinical Research Core Laboratory

    St Louis, Missouri · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.